Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 1 to 10 of 40 resources
-
Shooting Up: infections among people who inject drugs in the UK, 2019
Drug use in the United Kingdom is among the highest reported in Western Europe and people who inject drugs (PWID) experience stark health inequalities, with increased morbidity and early mortality. This report explores infections, as well as associated risks and behaviours, among people who inject drugs in the UK to the end of 2019. It also presents preliminary data on the impact of COVID-19 on PWID and services in 2020.UK, England, Northern Ireland, Scotland, Wales 28 Jan 2021 Reports & Research PDF -
Public Health England Hepatitis C in the UK 2020 Report
Public Health England published its annual 'Hepatitis C in the UK' report on 14th December 2020. This is the key national reporting document for hepatitis C and monitors the UK's progress towards its goal of eliminating the virus by 2030. This year's report includes details on the impact of COVID-19 on hepatitis C infection based on available data.UK, England, Northern Ireland, Scotland, Wales 14 Dec 2020 Reports & Research PDF -
Understanding the Sexual Health and Blood Borne Virus Risk Behaviours of Defined 'at risk' Groups
This report outlines the findings of research with drug users and the staff that support them related to harms associated with chemsex, transactional sex; and the use of image and performance enhancing drugs (IPEDs). Twos aims of the report were to describe the risk-taking behaviours in relation to drug taking, sexual health and transmission of BBV (blood borne virus) of the three target groups and inform the development of a training programme for services providers on sexual health and blood borne viruses for the three defined groups.Scotland 07 Sep 2020 Reports & Research PDF -
Summary Report: Hepatitis C services in Scotland during and beyond the Covid-19 outbreak - August 2020
With the Covid-19 outbreak having caused significant disruption to health services in Scotland, including those for hepatitis C, as well as drug and alcohol services, HCV Action organised a webinar to discuss how services and the drive to elimination in Scotland have been affected. This report provides a summary of the remarks from each of the four speakers and the Q&A which followed.Scotland Case study, Reports & Research, Tools & Templates, Strategy & Planning PDF -
HCV Action webinar: Hepatitis C services in Scotland during and beyond Covid-19
With the Covid-19 outbreak having caused significant disruption to healthcare services, including those for hepatitis C, this webinar was organised to discuss how services have been affected in Scotland and explore how hepatitis C services can most effectively be re-established as we emerge from the early phase of the outbreak. The webinar featured contributions from the following speakers: Professor John Dillon - Clinical Lead for Blood Borne Viruses, NHS Tayside Leon Wylie - Lead Officer, Hepatitis Scotland Rachel Halford - CEO, The Hepatitis C TrustScotland 05 Aug 2020 Training, Tools & Templates, Strategy & Planning Video -
Guidance on Contingency Planning for People who use Drugs and COVID-19: Version 2.0
This Scottish Drugs Forum-produced guidance is aimed at those planning and designing services as well as those managing and delivering services for people who use drugs, in particular those people on opioid substitution therapy (OST) and people who inject drugs. The guidance includes a section on blood borne virus (BBV) testing, noting that "all delayed BBV results from dry blood spot tests must be proactively followed up in a timely manner once COVID-19 related restrictions allow".Scotland 13 May 2020 Tools & Templates, Strategy & Planning PDF -
Staying Alive in Scotland: Strategies to Prevent Drug Deaths
This updated toolkit, a partnership between the Scottish Government and Scottish Drugs Forum, updates the original report produced three years ago. The resource notes that DAA treatments for hepatitis C provide an opportunity to prevent drug-related deaths, but that opportunities to test for hepatitis C are being missed.Scotland 20 Dec 2019 Reports & Research PDF -
Scotland’s Hepatitis C Action Plan: Achievements of the First Decade and Proposals for a Scottish Government Strategy (2019) for the Elimination of both Infection and Disease
This report reflects on how the Scottish Government's Hepatitis C Action Plan was established and what it has achieved a decade after its launch. It also reflects on changing Government policy over this time and sets out future policy to achieve the elimination of hepatitis C.Scotland 31 Jul 2019 Reports & Research, Strategy & Planning PDF -
Hepatitis C: interventions for patient case-finding and linkage to care
Published in July 2019 this review summarizes the evidence for interventions to increase case-finding and linkage to care for hepatitis C-infected patients, in order to support commissioning and provision of evidence-based interventions as part of efforts to achieve hepatitis C (HCV) elimination as a major public health threat in the UK.UK, England, Northern Ireland, Scotland, Wales 30 Jul 2019 Reports & Research PDF -
Surveillance of hepatitis C testing, diagnosis and treatment in Scotland, 2019 update
This Health Protection Scotland report outlines that there were 1,423 new diagnoses of hepatitis C antibody-positivity in Scotland in 2018, the lowest number of new hepatitis C antibody diagnoses in Scotland since 1996. It is estimated that approximately 21,000 individuals were living with chronic hepatitis C infection in Scotland by the end of 2018 and approximately 10,500 of these have been diagnosed. A total of 2,609 individuals were initiated onto hepatitis C treatment during financial year 2018/19.Scotland 23 Jul 2019 Reports & Research PDF